Skip to main content
Oncology
Breast Cancer
- Advanced Breast Cancer (A5481082) Observational
- Breast Cancer Survivors, Cognitive Impairment, (REMEMBER) (WF 97116)
- Breast Cancer, Young Women, Pregnancy Outcomes (POSITIVE) (A221405)
- Breast or Gynecologic Cancer, Improving Sexual Desire (NRG-CC0044)
- HER2 Negative Primary Breast Cancer, gBRCA1/2 Mutations and High Risk (NSABP B-55)
- HER2- Positive Breast Cancer, Brain Metastasis (RTOG 1119)
- High Risk, Node-Positive, Early Stage (NSABP B-58)
- High-Risk; Hormone Receptor-Positive and HER2/Neu Negative (S1207)
- Post Mastectomy Radiation w/Breast Reconstruction (A221505)
- Post-Mastectomy and Post-Lumpectomy; Positive Axillary Nodes (NSABP B-51)
- Screening Mammogram (TMIST) (EA1151)
- Solid Tumors, Blood Sample Collection to Evaluate Biomarkers (2018-01)
- Stage I-II Breast Cancer, MRI and Mammography Before Surgery (A011104)
- Triple Negative Breast Cancer (RX-5902)
- Triple Receptor-Negative Breast Cancer (S1418/BR006)
- Triple-Negative Basal-Like Breast Cancer (EA1131)
- Triple-Negative, Node-Positive or High-Risk Node-Negative (NRG-BR003)
- Weight Loss - Breast Cancer (A011401) (BWEL)Accepting Participants
Gastrointestinal Cancer
- Advanced Cancer, ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor (QUILT-3.055)
- Advanced Solid Tumors w/ FGF/FGFR Aberrations (TPU-TAS-120-101)
- Cholangiocarcinoma, Nonresectable or Metastatic IDH1 Mutation (AG120-C-005)
- Colon or Rectal Cancer, Stage I-III, Financial Burden Assessment (EAQ162CD)
- Colorectal Cancer, Cognitive Impairment (URCC 16092)
- Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer (NRG GI004)
- Liver, Non-resectable, (RESIN) Registry
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer (EA2165)
- Pancreatic Adenocarcinoma, Metastatic (ABI-007-PANC009)
- Pancreatic Adenocarcinoma, Metastatic (NLG2104)
- Pancreatic Cancer, Metastatic (RX-3117)
- Solid Tumors, Blood Sample Collection to Evaluate Biomarkers (2018-01)
Precision Medicine & Rare Tumors
- Advanced Cancer, ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor (QUILT-3.055)
- Advanced Solid Tumors w/ FGF/FGFR Aberrations (TPU-TAS-120-101)
- Germ Cell Tumor, Pediatric and Adult Patients (COG AGCT1531)
- HER2 Negative Primary Breast Cancer, gBRCA1/2 Mutations and High Risk (NSABP B-55)
- Leukemia, Chronic Myeloid (S1712)
- Lung Cancer, Squamous Cell, Lung-MAP Screening (S1400)
- Lymphoma, Diffuse Large B-Cell, Treatment Naïve (DB102-02)
- Lymphoma, Hodgkin (CA209655) Observational
- Lymphoma, Mantle Cell, Previously Treated (AFT-32)
- Melanoma, Stage III-IV BRAF Mutant (S1320)
- Merkel Cell Carcinoma, Advanced (A091605)
- Merkel Cell Carcinoma, Resected (EA6174)
- Non-small Cell Lung Cancer ALCHEMIST (A151216)
- Non-small Cell Lung Cancer NSCLC, EGFR Mutant (A081105)
- Solid and Liquid Tumors: Newly Diagnosed With No Treatment Started (GRAIL-001) Observation
- Solid Tumors (eFT508-0010)
- Solid Tumors or Lymphomas; MATCH (EAY131)
- Solid Tumors, Rare Tumor Types (S1609)
Thoracic Cancer
- Advanced Cancer, ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor (QUILT-3.055)
- Lung Cancer, Squamous Cell, Lung-MAP Screening (S1400)
- Lung Cancer, Survivors (RELAX) (WF01213)
- LUNGMAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer, (Screening Study)
- Non-small Cell Lung Cancer (NSCLC), Metastatic (NRG LU-002)
- Non-small Cell Lung Cancer ALCHEMIST (A151216)
- Non-small Cell Lung Cancer NSCLC, EGFR Mutant (A081105)
- Non-small Cell Lung Cancer NSCLC; Stages I-II; African-American, (WF01414) Observation
- Non-small Cell Lung Cancer, Early Stage, Resected, Harboring ALK (E4512)
- Non-small Cell Lung Cancer, Previously Treated (SWOG LungMAP)
- Small Cell Lung Cancer, Relapsed or Refractory, Second-Line (DIV-SCLC-301)
- Solid Tumors, Blood Sample Collection to Evaluate Biomarkers (2018-01)
Symptom Management & Cancer Control
- All Disease Sites; Completed Treatment; Insomnia Study (URCC 14040)
- All Disease Sites; Health Disparities (DCP-001)
- Breast Cancer Survivors, Cognitive Impairment, (REMEMBER) (WF 97116)
- Breast Cancer, Young Women, Pregnancy Outcomes (POSITIVE) (A221405)
- Breast or Gynecologic Cancer, Improving Sexual Desire (NRG-CC0044)
- Colorectal Cancer, Cognitive Impairment (URCC 16092)
- Head and Neck, Squamous Cell Carcinoma, Oral Mucositis (IDR-OM-02)
- Lung Cancer, Survivors (RELAX) (WF01213)
- Non-small Cell Lung Cancer NSCLC; Stages I-II; African-American, (WF01414) Observation
- Ovarian, Fallopian Tube, and Primary Peritoneal, Diet & Physical Activity (GOG-0225)
- Screening Mammogram (TMIST) (EA1151)
- Stage I-II Breast Cancer, MRI and Mammography Before Surgery (A011104)
- Survivors, Work Ability in Young Adult Survivors (WF 10217)
- Weight Loss - Breast Cancer (A011401) (BWEL)Accepting Participants
Cutaneous & Sarcoma Cancer
Cancer Care Delivery Research (CCDR)
Hematologic Cancer
- Leukemia, Acute Lymphocytic (ALL), Adolescent & Young Adult (ACCL16N1CD)
- Leukemia, Acute Promyelocytic (EA9131) Observational
- Leukemia, Chronic Lymphocytic (CLL), Untreated Older Patients (A041702)
- Leukemia, Chronic Lymphocytic (CLL), Untreated Younger Patients (EA9161)
- Leukemia, Chronic Lymphocytic (PCYC-1134M), Registry
- Leukemia, Chronic Myeloid (S1712)
- Lymphoma, Diffuse Large B-Cell, Relapsed or Refractory (1562-201)
- Lymphoma, Diffuse Large B-Cell, Treatment Naïve (DB102-02)
- Lymphoma, Hodgkin (CA209655) Observational
- Lymphoma, Mantle Cell, Previously Treated (AFT-32)
- Multiple Myeloma, Refractory to Lenalidomide (A061202)
- Multiple Myeloma, Untreated, Stem Cell Transplant Not Planned (54767414MMY3019)
- Multiple Myeloma: 1st Line Therapy (E1A11)
- Myelodysplastic Syndromes & Acute Myeloid Leukemia, (Connect® MDS/AML) Observational
- Myelodysplastic Syndromes (MDS) (NHLBI-MDS) Observational
- Myelofibrosis or Essential Thrombocythemia (INCB-MA-MF-401) Registry
- Plasmacytoma of the Bone (A061402)
- A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not PlannedAccepting Participants
- Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies (2018-02)Accepting Participants
Other
Wound Healing - Infectious Disease
